Relation of paraoxonase1, arylesterase and lipid profile in ischemic Stroke patients

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 11, 2015, Pages BC01-BC03

  Chawhan, Seema Sanjay ^a   Mogarekar, Mukund R ^b   Wagh, Reena V ^a   Das, Rajkumar R ^a   Pramanik, Sanjay S ^a   Sonune, Sanjay M ^a   Chawhan, Sanjay M ^a  

^a SSH and GMCH ^*  (India)

^b SRTR   (India)

Author keywords

Atherosclerosis; HDL; LDL oxidation; Paraoxon

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; LIPID ANALYSIS; SPECTROPHOTOMETRY;

EID: 84946573486     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/15345.6707     Document Type: Article

References (26)

1. Dalal P, Bhattacharjee M, Vairale J, Bhat P. UN millennium development goals: can we halt the stroke epidemic in India? Ann Indian Acad Neurol. 2007;10:130-36.
2. Li SC, Schoenberg BS, Wang C, et al. Cerebrovascular disease in the People’s Republic ofChina: epidemiologic and clinical features. Neurology. 1985;35:1708-13.
3. Wade S, Joey E, Claiborn S. Cerebrovascular Disease. In: Longo DL, ed. Harrison’s Principles of Internal Medicine. Vol 2, 17th edn. The McGraw-Hill Companies Inc., 2008;3270-92.
4. Frederick J. Schoen. Blood Vessels. Robbins and Cotran, PATHOLOGIC BASIS OF DISEASE. 7th Edition. 2005: 512-25.
5. Lusis AJ, Mar R, Pajukanta P. Genetics of Atherosclerosis. A nnu Rev Genomics Hum Genet. 2004;5:189–218.
6. Bianca F, Oiknine J, Shlomo K, Limor B, Marielle K, Michael A. Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL. Free Radical Biology & Medicine. 1997;23:34–46.
7. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73–76.
8. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum Paraoxonase/Arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-1 stabilises activity. Arterioscler Thromb Vasc Biol. 1999;19:2214-25.
9. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46:1239–47.
10. Davies H, Richter RJ, Kiefer M, Broomfield CA, Sowalla J, Furlong CE. The human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet. 1996;14:334–36.
11. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243-53.
12. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286:152–54.
13. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/ paraoxonase: selective action of human Paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol. 1998;18:1617-24.
14. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Praoxonase-1 oxidized LDL- induced MCP-1 production by endothelial cells. Biochem Biophysic Res Comm. 2004;318:680-83.
15. Aviram M, Rosenblat M, Bisgaier CL. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest.1998;101:1581–90.
16. Roeschlau P, Bernt E, Gruber W. Enzymatic determination of serum cholesterol. Clin Chem Clin Biochem. 1974;12:226.
17. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11:583-95.
18. McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidase-coupled [18] method for the colorimetric determination of serum triglycerides. Clin Chem. 1983;29:538-42.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of [19] low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem.1972;18:499-502.
20. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35:1126-38.
21. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology. 2004;63:1868-75.
22. Aviram M, Rosrnblat M. Paraoxonases 1,2,and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radical Biology & Medicine. 2004;3:1304–16.
23. Mackness MI, Durrington PN. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243–53.
24. Zuliani G, Vigna GB, Fellin R. The anti-atherogenic properties of HDL particles. International Congress Series. 2007;1303:103–10.
25. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid arteriosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000;101:2510–17.
26. Kim NS, Kang K, Cha MH, Kang BJ, Yu BC, Kim YS, et al. Decreased paraoxonase -1 activity is a risk factor for ischemic stroke in Koreans. Biochem Biophysl Res Commun. 2007;364:157-62.